

Intermittent vismodegib dosing to treat multiple basal-cell carcinomas

Citation for published version (APA):

Mosterd, K. (2017). Intermittent vismodegib dosing to treat multiple basal-cell carcinomas. *Lancet oncology*, 18(3), 284-286. [https://doi.org/10.1016/S1470-2045\(17\)30079-7](https://doi.org/10.1016/S1470-2045(17)30079-7)

Document status and date:

Published: 01/03/2017

DOI:

[10.1016/S1470-2045\(17\)30079-7](https://doi.org/10.1016/S1470-2045(17)30079-7)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

that even when treatment toxicity is quickly addressed and managed, ipilimumab has a small but relevant effect on global quality of life.

Far more important than the nuanced determinations of a threshold difference for global scores, however, is the clear clinical applicability of the HRQoL information gathered on EORTC 18071. The findings provide textured evidence about the time course of symptom effects, and the expected recovery after treatment, that is not obtained from toxicity grade reporting alone. Because most patients with melanoma want some role in decision making about their care,⁶ and given the potential severe toxicities of ipilimumab versus the potential benefits of treatment, the HRQoL findings can inform patients about how treatment might affect their quality of life. Importantly, the HRQoL findings can help define treatment value, informing health policy. Moving forward, HRQoL data will undoubtedly be even more important in trials comparing active therapies.


*Michael Brundage, Timothy Hanna

Cancer Care and Epidemiology, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada
michael.brundage@krcc.on.ca

We declare no competing interests.

- 1 Eggermont AM, Chiarion-Sileni V, Grob JJ et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. *Lancet Oncol* 2015; **16**: 522–30.
- 2 Eggermont AM, Chiarion-Sileni V, Grob JJ et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. *New Engl J Med* 2016; **375**: 1845–55.
- 3 Coens C, Suci V, Chiarion-Sileni V. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. *Lancet Oncol* 2017; published online Feb 2. [http://dx.doi.org/10.1016/S1470-2045\(17\)30015-3](http://dx.doi.org/10.1016/S1470-2045(17)30015-3).
- 4 Brandberg Y, Aamdal S, Bastholt L et al. Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b. *Eur J Cancer* 2012; **48**: 2012–19.
- 5 Revicki DA, van den Eertwegh AJ, Lorigan P et al. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. *Health Qual Life Outcomes* 2012; **10**: 66.
- 6 Albrecht KJ, Nashan D, Meiss F, Bengel J, Reuter K. Shared decision making in dermatology: preference for involvement of melanoma patients. *Melanoma Res* 2014; **24**: 68–74.

Intermittent vismodegib dosing to treat multiple basal-cell carcinomas



P. Marazzi/Science Photo Library

Many basal-cell carcinomas can be treated effectively by uncomplicated surgical excision.¹ Longstanding tumours, which are often neglected or maltreated, might become inoperable. Targeted treatment with Smoothed homologue (SMO) inhibitors, such as vismodegib and sonidegib, has shown part or complete clearance.^{2,3} In patients with advanced basal-cell carcinoma, however, 1 year of vismodegib treatment was associated with complete response in only 34%, and resistance seemed to be a serious problem.² Furthermore, in 80% of the patients who received continuous vismodegib in that study, treatment was stopped most frequently because of adverse events.² In contrast to advanced basal-cell carcinoma, multiple basal-cell carcinomas is a chronic condition that needs lifelong treatment. The continuous dosing schedules currently used make long-term treatment impossible, but no data supporting implementation of treatment breaks are available.

In *The Lancet Oncology*, Brigitte Dréno and colleagues⁴ investigated in the MIKIE study two intermittent

vismodegib dosing schedules to assess whether sufficient drug activity could be achieved to inhibit the growth of basal-cell carcinomas while improving tolerability with non-dosing periods. Adults with multiple basal-cell carcinomas amenable to surgery, including those with basal-cell nevus (Gorlin) syndrome, were randomly assigned to receive either 150 mg vismodegib per day for 12 weeks, then three rounds of 8 weeks of placebo daily followed by 12 weeks of 150 mg vismodegib daily (treatment group A) or 150 mg vismodegib per day for 24 weeks, then three rounds of 8 weeks of placebo daily followed by 8 weeks of 150 mg vismodegib daily (treatment group B). The basal-cell carcinomas treated in MIKIE differ from the advanced basal-cell carcinomas treated in previous clinical studies of SMO inhibitors. In general, advanced basal-cell carcinomas have been present and untreated for years or have recurred, are often large, might have deeply invasive structures, and are most commonly located in the head and neck region.² Treatment of multiple basal-cell carcinomas

Published Online

February 7, 2017

[http://dx.doi.org/10.1016/S1470-2045\(17\)30079-7](http://dx.doi.org/10.1016/S1470-2045(17)30079-7)

See [Articles](#) page 404

is usually much less challenging. The tumours might be found anywhere on the body and surgical excision is usually done under local anaesthesia without complications. The high numbers of basal-cell carcinomas, however, cause substantial physical and psychological burdens. Patients with basal-cell nevus syndrome might have more than 1000 basal-cell carcinomas during their lives.⁵ Non-invasive treatments are, therefore, very desirable in this group of patients, but none has yet been approved.

The primary endpoint of MIKIE, mean number of basal-cell carcinoma lesions at the end of treatment (week 73), was reduced from baseline in both groups: by 62.7% (95% CI 53.0–72.3) in treatment group A and 54.0% (43.6–64.4) in treatment group B. The safety profiles were similar overall in the two treatment groups.

These results provide important information about the degrees of drug activity and safety that can be achieved with intermittent dosing schedules. Furthermore, they elucidate the benefits and limitations of an SMO inhibitor in the treatment of patients with multiple basal-cell carcinomas, including those with basal-cell nevus syndrome. The sustained activity with the intermittent dosing schedules tested is promising. Given the side-effects of SMO inhibitors, the evidence might also be useful for informing the treatment of advanced basal-cell carcinoma. Remarkably, the initial 12 weeks of vismodegib in treatment group A led to tumour shrinkage that continued during the 8-week treatment break when placebo was given, and was similar to that seen in patients in treatment group B who were still receiving vismodegib as part of the first 24-week course.

The number of treatment-emergent adverse events in treatment group B was higher, adherence to treatment was lower, and treatment activity was less than in treatment group A. Additionally, tumour size was reduced more in treatment group A than in treatment group B, and more patients had at least 50% reduction in number of basal-cell carcinomas from baseline to the end of treatment. Thus, 12 weeks of vismodegib treatment followed by rounds of 8-week treatment breaks and 12 weeks of treatment seems to be the better choice of the two regimens (although this was not formally compared). However, I wonder whether even this regimen is too stringent.

108 (47%) of 229 patients discontinued treatment, mostly because of treatment-emergent adverse events. The range of adverse events seems to be similar to that seen in studies of continuous dosing,² although fewer were grade 3 or worse despite the median treatment duration being almost twice as long. No patient achieved 100% clearance of basal-cell carcinomas. Furthermore, new tumours will develop after treatment is stopped. Longer treatment breaks would decrease the effect of the drug even further.⁶ The question needs to be posed, therefore, of whether it is worth postponing surgery for a treatment that leads to grade 3 or worse treatment-emergent adverse events in around a third of patients and serious treatment-related events in around 4% in a relatively young and healthy population. Further-extended follow-up is needed to investigate long-term effects on patients' health and how long it takes in tumour-free skin, which can still harbour histologically detectable basal-cell carcinomas, for treated tumours to recur after treatment is stopped.^{6,7} Recurring tumours might not be as easy to treat as the primary tumours, and might need surgery with increased excision margins.⁸ The risk of discontinuous growth, which can affect the reliability of (Mohs) surgery, is also a concern.⁹

Because the on-target side-effects of vismodegib might hamper lifelong treatment, the acceptability of systemic intermittent treatment with this drug warrants further investigation. Although so far not very successful, topical application of SMO inhibitors might be the only long-term method of administration that can be tolerated.¹⁰

Klara Mosterd

Department of Dermatology, Maastricht University Medical Centre, 6202 AZ Maastricht, Netherlands; GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, Netherlands
k.mosterd@mumc.nl

I have acted as a consultant for Novartis and Roche in relation to Hedgehog-pathway inhibitors.

- 1 Mosterd K, Krekels GA, Nieman FH, et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. *Lancet Oncol* 2008; **9**: 1149–56.
- 2 Basset-Seguin N, Hauschild A, Grob JJ, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. *Lancet Oncol* 2015; **16**: 729–36.
- 3 Dummer R, Guminski A, Gutzmer R, et al. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. *J Am Acad Dermatol* 2016; **75**: 113–25. e5.

- 4 Dréno B, Kunstfeld R, Hauschild A, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. *Lancet Oncol* 2017; published online Feb 7. [http://dx.doi.org/10.1016/S1470-2045\(17\)30072-4](http://dx.doi.org/10.1016/S1470-2045(17)30072-4).
- 5 Kimonis VE, Singh KE, Zhong R, Pastakia B, Digiovanna JJ, Bale SJ. Clinical and radiological features in young individuals with nevoid basal cell carcinoma syndrome. *Genet Med* 2013; **15**: 79–83.
- 6 Tang JY, Ally MS, Chanana AM, et al. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol* 2016; **17**: 1720–31.
- 7 Ally MS, Aasi S, Wysong A, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. *J Am Acad Dermatol* 2014; **71**: 904–11. e1.
- 8 Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. *Br J Dermatol* 2008; **159**: 35–48.
- 9 Sand M, Bechara FG, Gambichler T, et al. Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study. *Ann Oncol* 2016; **27**: 332–38.
- 10 Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothed inhibitor. *J Invest Dermatol* 2011; **131**: 1735–44.

C/Can 2025: City Cancer Challenge, a new initiative to improve cancer care in cities

Published Online
February 3, 2017
[http://dx.doi.org/10.1016/S1470-2045\(17\)30083-9](http://dx.doi.org/10.1016/S1470-2045(17)30083-9)

Cancer and other non-communicable diseases (NCDs) enjoy an unprecedented global profile, yet of the 4 billion people living in cities today, few of them have access to high-quality cancer treatment outside of high-income countries.

The greatest financial and human effects of cancer are felt in low-income and middle-income countries (LMICs), which are least equipped to respond to this growing burden, and where rapid urbanisation is bringing other significant developmental challenges.¹ In 2016, 1·7 billion people—23% of the world’s population—lived in a city with at least 1 million inhabitants, and by 2030 this percentage is likely to increase to 27%.² Coordinated global efforts are urgently needed to improve cancer services to keep pace with the scale and the speed of this urbanisation process, with targeted efforts required to improve

the availability of affordable cancer technologies and essential cancer medicines.

The Union for International Cancer Control (UICC) has launched a new initiative, C/Can 2025: City Cancer Challenge, to support cities in accelerating equitable access to quality cancer services. Cities are already leading the way in cancer and NCD preventative measures through the creation of smoke-free environments, and by driving efforts to improve the quality of air for their citizens. C/Can 2025 will build on these efforts to promote health, and encourage and support cities to take the lead in the design, planning, and implementation of cancer services. Between now and 2025, the initiative will target over 200 cities to improve the health of at least 0·5 billion people worldwide. In 2017, the first three cities who have committed to C/Can 2025—Asunción (Paraguay), Cali (Colombia), and Yangon (Myanmar)—will undertake a comprehensive needs assessment to identify gaps in the delivery of cancer services, and will be supported by C/Can 2025 to develop plans for sustainable solutions that will increase the number of people with access to cancer treatment and care.

By taking an integrated health systems approach, C/Can 2025 has the potential to support improvements in cancer prevention, and help strengthen a city’s capacity to deliver public health services. These efforts will help reduce the incidence of cancer and other NCDs in cities, and also ensure patients are diagnosed as early as possible. Such interventions will be crucial in LMICs where major public health challenges place increasing pressures on urban health systems and can further exacerbate inequities in access to care.



Gadong/istock/Science Photo Library